About 9 results found for searched term "SL-01" (0.086 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3014 | SL-01 | Mdm2 |
| SL-01 is a p53-Mdm2 interaction inhibitor with IC50 of 3.18 μM. | ||
| M3099 | U-104 | Carbonic Anhydrase |
| MST-104; SLC-0111 | ||
| U-104 is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM, respectively, very low inhibition for CA I and CA II. | ||
| M3200 | SL 0101-1 | S6 Kinase |
| SL-0101-1 is a selective p90 RSK inhibitor for RSK2 with IC50 of 89 nM. | ||
| M8907 | Acecainide HCl | Others |
| ASL 601; N-acetylprocainamide | ||
| Acecainide HCl, also known as N-acetylprocainamide and ASL 601, is the N-acetylated metabolite of procainamide. | ||
| M21722 | Felezonexor (CBS9106) | CRM1 |
| CBS9106; SL-801 | ||
| Felezonexor (CBS9106; SL-801) is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity without affecting CRM1 mRNA levels. Felezonexor is also a reversible inhibitor of XPO1, inhibits nuclear export by covalently binding to Cys528 as well as by inducing the degradation of XPO1. | ||
| M24892 | Tagraxofusp | Fusion Proteins |
| SL-401 | ||
| Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib and Pomalidomide to suppress multiple myeloma (MM). | ||
| M27844 | Varlitinib tosylate | EGFR/HER2 |
| ASLAN001 tosylate; ARRY-334543 tosylate | ||
| Varlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively. | ||
| M28168 | HG6-64-1 | Raf |
| HMSL 10017-101-1 | ||
| HG6-64-1 is a potent and selective B-Raf inhibitor, with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. | ||
| M28464 | SL910102 | Angiotensin Receptor |
| SL910102 is a nonpeptide angiotensin AT1 receptor antagonist. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
